Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Recent announcements, achievements, and development milestones from PARI's pharmaceutical partners utilizing eFlow® Technology.
New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease
Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases
Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference
A new FDA Fast Track designation for Zambon
Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)